NOVARTIS

Kisqali (ribociclib) plus endocrine therapy (ET) reduces recurrence risk by 28.5% in HR+/HER2- early breast cancer, with benefits extending beyond three years and consistent across subgroups, including node-negative patients. Safety remains consistent with previous findings, and regulatory reviews are ongoing worldwide.

The Global Precision Medicine Market report covers industrial and commercial aspects, market driving forces, key players' strategies, and regional landscape. It includes detailed vendor profiles, market trends, share analysis, and forecasts from 2024 to 2032.

FDA approves Kisqali, a ribociclib-based treatment, in combination with an aromatase inhibitor for adjuvant therapy of HR+/HER2- stage II and III early breast cancer patients at high risk of recurrence, including those with node-negative disease. The approval is supported by the Phase III NATALEE trial results, which demonstrated a 25.1% reduction in disease recurrence risk and a well-tolerated safety profile.

FDA approves Novartis' Kisqali for HR+/HER2- early breast cancer to reduce recurrence risk, based on NATALEE trial results showing a 25.1% reduction in recurrence risk with Kisqali plus endocrine therapy vs. endocrine therapy alone.

Oliver Sartor interviews Jessica Jensen on radiopharmaceuticals in cancer treatment, discussing the patient-centric approach, isotope selection complexities, supply chain investment, and the potential of new isotopes. Jensen emphasizes the importance of precision medicine, cautious innovation, and the need for holistic thinking about dose delivery, expressing optimism about the future of radiopharmaceuticals with larger companies investing in the field.

Kisqali, a drug for metastatic breast cancer, now approved for earlier stages, reduces recurrence risk by 25% after three years. It's for HR-positive, HER2-negative breast cancer, stages two and three. Despite potential side effects and high cost, it offers hope for preventing cancer's return.

The HIMALAYA study's 5-year survival analysis shows 19.6% survival with STRIDE (durvalumab plus tremelimumab) vs 9.4% with sorafenib in unresectable hepatocellular carcinoma, with no new safety concerns.

Kelly Chibale, from a Zambian village to Cambridge and Scripps, founded the Holistic Drug Discovery and Development Centre (H3D) at the University of Cape Town in 2010. H3D, supported by research and funding partners, focuses on malaria, tuberculosis, and antibiotic-resistant diseases, developing MMV390048, the first small-molecule clinical candidate discovered by an Africa-led team. Chibale emphasizes the need for global recognition and collaboration with African scientists to address diverse health challenges and foster innovation.

Novo Nordisk's liraglutide Phase III trial in children under 12 showed a -7.4% BMI difference favoring liraglutide. Pfizer's maplirpacept saw PTSR drop after Phase I termination. Vaxcyte's VAX-31 vaccine reported positive Phase I/II data. Atsena Therapeutics's ATSN-101 in rare disease ophthalmology met all endpoints. Les Laboratoires's oncology Phase I trial was terminated.

The Renal Cell Carcinoma Clinical Trial Pipeline Market is projected to grow significantly from 2024 to 2031, driven by technological innovations, rising demand, and regulatory changes. The market is segmented by type and application, with key players including Amgen, AstraZeneca, and Pfizer. Clinical trials focus on novel therapies, drug combinations, and targeted treatments, aiming to improve outcomes for renal cell carcinoma patients.